Antibiotic News and Research

RSS

Antibiotics are drugs used to treat infections caused by bacteria and other microorganisms.

AMCP supports legislation to prohibit financial agreements for delaying marketing of lower-cost generic drugs

The Academy of Managed Care Pharmacy (AMCP) supports the inclusion of legislative language similar to S. 369 — the Preserve Access to Affordable Generics Act — in appropriations legislation now under consideration by the Senate. S. 369 would prohibit financial agreements between brand-name and generic pharmaceutical manufacturers to delay the marketing of lower-cost generic drugs.

14 Sep 2010

Progenics Pharmaceuticals presents findings of humanized monoclonal antibodies against C. difficile bacterium

Progenics Pharmaceuticals, Inc. today presented preclinical findings for its humanized monoclonal antibodies against the disease-causing toxins produced by the bacterium Clostridium difficile.

14 Sep 2010

Rib-X Pharmaceuticals presents positive preclinical data for delafloxacin at ICAAC Conference

Rib-X Pharmaceuticals, Inc., a development-stage antibiotics company with a broad product pipeline based on its innovative discovery platform, today announced the presentation of positive preclinical data for delafloxacin in four poster sessions at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

14 Sep 2010

NIH awards QuantaLife $6 million to build platform for detecting MRSA infections

QuantaLife, a new life science tool company developing the third generation of PCR, has received an NIH grant totaling ~$6 million over 5 years for the development of rapid, cost-effective technology for detecting methicillin-resistant Staphylococcus aureus (MRSA) infections. The grant, from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), part of the National Institutes of Health, will fund the project.

14 Sep 2010

Trius Therapeutics reports torezolid antibiotic resistance mechanism for MRSA strains

Trius Therapeutics, Inc. today reported new findings on torezolid phosphate (TR-701), a second generation oxazolidinone antibiotic now in Phase 3 clinical development. The data elucidate the mechanism by which torezolid retains full activity against clinical isolates of Staphylococcus aureus (S. aureus) carrying the cfr gene which confers resistance to first generation oxazolidinones such as linezolid, marketed by Pfizer as Zyvox.

14 Sep 2010

Experts warn dip in antibiotic R&D could lead to treatment challenges

The 50th annual meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) kicked off in Boston on Sunday with experts warning that a "slowdown" in research on antibiotic development could result in treatment challenges.

14 Sep 2010

Study finds antibiotic safe for treatment of stroke and good companion therapy for tPA

An antibiotic appears to be a safe treatment for stroke and a good companion therapy for tPA, the clot buster that is currently the only FDA-approved drug therapy, researchers report.

13 Sep 2010

Tetraphase Pharmaceuticals presents TP-434 drug candidate clinical data

Tetraphase Pharmaceuticals, Inc., yesterday presented new clinical and preclinical data for its lead drug candidate, TP-434, which demonstrated the novel antibiotic as a once daily intravenous (I.V.) monotherapy capable of treating multidrug-resistant gram-negative pathogens while also having potency and broad spectrum coverage of other serious and multidrug resistant gram-positive pathogens.

13 Sep 2010

Anacor Pharmaceuticals files registration statement with U.S. SEC for initial public offering

Anacor Pharmaceuticals, Inc. today announced that it has filed a registration statement with the U.S. Securities and Exchange Commission ("SEC") relating to the proposed initial public offering of shares of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined. All shares of the common stock to be sold in the offering will be offered by Anacor.

13 Sep 2010

MRSA infection hVISA linked to mortality

A MRSA infection with a reduced susceptibility to the potent antibiotic drug vancomycin is linked to high mortality, according to a Henry Ford Hospital study.

12 Sep 2010

AAOS releases clinical practice guideline for periprosthetic joint infection diagnosis

The American Academy of Orthopaedic Surgeons (AAOS) recently approved and released an evidence-based clinical practice guideline on the diagnosis of periprosthetic joint infections of the hip and knee. Clinical practice guidelines are one avenue the Academy uses to ensure that patients receive high quality care.

10 Sep 2010

Researchers find minocycline antibiotics effective for fragile X syndrome

One of the antibiotics most commonly prescribed to treat adolescent acne can increase attention spans and communication and decrease anxiety in patients with fragile X syndrome, the most common inherited cause of mental impairment, according to a new survey study that is the first published on parents' reports of their children's responses to treatment with the medication.

9 Sep 2010

Federal appeals court declines to reconsider 'pay-for-delay' on generic drugs

A federal appeals court on Tuesday said it will not revisit its decision to uphold settlements that allow pharmaceutical companies to pay competitors to keep generic versions of their drugs off the market, The Wall Street Journal reports. "In April, the U.S. Second Circuit Court of Appeals [in New York] affirmed the legality of a settlement in which Bayer AG, in essence, paid Barr Pharmaceuticals Inc., a potential generic competitor, to drop its patent challenge to Cipro, a Bayer antibiotic."

9 Sep 2010

Concerted action on antibiotic resistance discussed at Uppsala meeting

For 70 years the world has mismanaged the common good of antibiotics. The result is a growing global burden of antibiotic resistance, threatening to take health care back to an era where ordinary infections might once again become fatal.

9 Sep 2010

NovaBay Pharmaceuticals to deliver new data on Aganocide compounds at ICAAC Conference

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, will deliver four poster presentations on its compounds at the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

9 Sep 2010

Tetraphase announces 13 data presentations on TP-434 broad spectrum antibiotic at ICAAC 2010

Tetraphase Pharmaceuticals, Inc., today announced that 12 poster presentations and an oral summary presentation on preclinical and clinical data for its lead drug candidate, TP-434, will be presented at the 2010 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Boston, MA, being held September 12 -15 at the Boston Convention and Exhibition Center.

9 Sep 2010

Trius Therapeutics announces presentations from drug development programs at 50th ICAAC

Trius Therapeutics, Inc. announced today that the results of multiple studies from its drug development programs, including its lead antibiotic drug candidate torezolid phosphate (TR-701), will be presented in poster presentations at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting in Boston September 12-15.

8 Sep 2010

Fluctuation in PCV-7 vaccine dosing time increases pneumococcal serotype 19A strains: Study

Infants who received heptavalent pneumococcal conjugate vaccination (PCV-7) at 2, 4, and 11 months were more likely than unvaccinated controls to have nasopharyngeal (in the nasal passages and upper part of the throat behind the nose) acquisition of pneumococcal serotype 19A, a leading cause of respiratory pneumococcal disease, according to a study in the September 8 issue of JAMA.

8 Sep 2010

Also in Global Health News: India's antibiotic use; Abstinence curriculum in China; Child, maternal health in India; Plumpy'nut; PEPFAR funds to Uganda

"The health ministry has formed a committee to frame a policy for antibiotic use, following an uproar over a Lancet study that traced a drug-resistant bacterial superbug's origins to India," LiveMint.com reports. The panel will also look into the "excessive use of antibiotics among Indians," partly fueled by self-medication, that has increased resistance to the drugs. The article notes that the Indian government "rejected the findings of the report" but has "taken note of a lack of policy on antibiotics" (Pandeya, 9/3).

7 Sep 2010

Bend Research expands hot-melt extrusion pharmaceutical manufacturing capabilities

Bend Research Inc., a leading independent drug-formulation development and manufacturing company, announced today that it is expanding its pharmaceutical manufacturing capabilities for hot-melt extrusion.

7 Sep 2010

Antibiotic News and Research

Further Reading

AMCP supports legislation to prohibit financial agreements for delaying marketing of lower-cost generic drugs

Progenics Pharmaceuticals presents findings of humanized monoclonal antibodies against C. difficile bacterium

Rib-X Pharmaceuticals presents positive preclinical data for delafloxacin at ICAAC Conference

NIH awards QuantaLife $6 million to build platform for detecting MRSA infections

Trius Therapeutics reports torezolid antibiotic resistance mechanism for MRSA strains

Experts warn dip in antibiotic R&D could lead to treatment challenges

Study finds antibiotic safe for treatment of stroke and good companion therapy for tPA

Tetraphase Pharmaceuticals presents TP-434 drug candidate clinical data

Anacor Pharmaceuticals files registration statement with U.S. SEC for initial public offering

MRSA infection hVISA linked to mortality

AAOS releases clinical practice guideline for periprosthetic joint infection diagnosis

Researchers find minocycline antibiotics effective for fragile X syndrome

Federal appeals court declines to reconsider 'pay-for-delay' on generic drugs

Concerted action on antibiotic resistance discussed at Uppsala meeting

NovaBay Pharmaceuticals to deliver new data on Aganocide compounds at ICAAC Conference

Tetraphase announces 13 data presentations on TP-434 broad spectrum antibiotic at ICAAC 2010

Trius Therapeutics announces presentations from drug development programs at 50th ICAAC

Fluctuation in PCV-7 vaccine dosing time increases pneumococcal serotype 19A strains: Study

Also in Global Health News: India's antibiotic use; Abstinence curriculum in China; Child, maternal health in India; Plumpy'nut; PEPFAR funds to Uganda

Bend Research expands hot-melt extrusion pharmaceutical manufacturing capabilities

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News